SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

  1. Redin, E.
  2. Garmendia, I.
  3. Lozano, T.
  4. Serrano, D.
  5. Senent, Y.
  6. Redrado, M.
  7. Villalba, M.
  8. De Andrea, C.E.
  9. Exposito, F.
  10. Ajona, D.
  11. Ortiz-Espinosa, S.
  12. Remirez, A.
  13. Bertolo, C.
  14. Sainz, C.
  15. Garcia-Pedrero, J.
  16. Pio, R.
  17. Lasarte, J.
  18. Agorreta, J.
  19. Montuenga, L.M.
  20. Calvo, A.
Journal:
Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426

Year of publication: 2021

Volume: 9

Issue: 3

Type: Article

DOI: 10.1136/JITC-2020-001496 GOOGLE SCHOLAR lock_openOpen access editor HANDLE: https://hdl.handle.net/10171/62289
Dadun. Depósito Académico Digital de la Universidad de Navarra: lock_openOpen access Externo lock_openOpen access Handle

Sustainable development goals